Product Reports Resources Pricing Login Book a demo

Diagenode

Biotech & Life Sciences · Seraing, Belgium · Founded 2003

Epigenomics tools and diagnostics powering advanced disease insights MoreLess

Diagenode, now operating as Hologic Diagenode, is a Belgian life sciences company specializing in epigenomics profiling services, molecular diagnostics and sample preparation tools for next‑generation sequencing, proteomics and epigenetics research. Founded in 2003 in Liège/Seraing, it has built a comprehensive portfolio of instruments such as the Bioruptor sonicators, high‑quality reagent kits and extensively validated antibodies that standardize critical workflows including chromatin shearing, ChIP‑seq, ATAC‑seq and DNA methylation assays. These products are used globally by academic laboratories, biotechs, pharmaceutical companies and clinical research organizations to explore gene regulation and uncover novel biomarkers. ​ Beyond tools, Diagenode offers full‑stack epigenomics and RNA‑seq services, covering experimental design, wet‑lab execution and advanced bioinformatics analysis. Its service offering spans chromatin immunoprecipitation sequencing (ChIP‑seq), ATAC‑seq, whole‑genome and reduced representation bisulfite sequencing (WGBS, RRBS), and a range of RNA‑sequencing approaches, including small RNA and CATS‑based low‑input workflows. This integrated model enables customers to outsource complex projects such as genome‑wide mapping of histone marks, methylation profiling and transcriptome characterization, accelerating discovery while ensuring data quality and reproducibility. ​ ​ In parallel, Diagenode has built a CE‑marked molecular diagnostics menu of more than 30 real‑time PCR assays targeting infectious agents involved in sexually transmitted infections, respiratory diseases, meningitis and gastroenteritis, among others. These assays, combined with the company’s epigenetics expertise, position it at the interface of research and clinical application, supporting both fundamental science and translational diagnostics development. Hologic’s 2021 acquisition of Diagenode, valuing the company at approximately $159 million on annual revenues above $30 million, reflects the strategic importance of its technologies and European footprint in the broader molecular diagnostics market. ​ Keywords: Diagenode; Hologic Diagenode; epigenetics; epigenomics; DNA methylation; ChIP‑seq; ATAC‑seq; RNA‑seq; small RNA sequencing; next‑generation sequencing; molecular diagnostics; PCR assays; infectious disease diagnostics; life science tools; laboratory instruments; sample preparation; bioinformatics services; biomarker discovery; Belgium; Liège.

Valuation $100–500M
Revenue $10–50M
Headcount 100–500
Total funding $10–50M
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Diagenode and the history behind them.

Company overview

Diagenode company information

The essential company record, classifications and operating signals in one place.

Status
Acquired
Founded
2003
Headquarters
Seraing, Belgium
Employees
123
Open positions
2
Dealroom signal
66.6
Investment activity
1 companies · latest Aug 2018
Capital deployed
Preferred round
ACQUISITION
client focusb2btechnologyHardwaretechnologyDeep Techsub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorDNAsectorInfections and Infectious DiseasessectorGenetics and genomicssectorSequencingsectorMolecular BiologysectorEpigeneticssectorGenome Engineering

Valuation & funding

Diagenode funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONExit Mar 2021 $159M $159M Hologic
GRANTOther financing Jan 2018 $913K Undisclosed
GRANTOther financing Oct 2016 $539K Undisclosed
EARLY VCEquity / VC Jun 2016 $8.3M $33M Epimede · Wallonie Entreprendre · Capricorn Partners
GRANTOther financing Jan 2016 $187K Undisclosed
GRANTOther financing Nov 2013 Undisclosed
Showing 6 recorded eventsUnlock the complete deal history →

Financials

Revenue, earnings and profit over time

Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.

YearRevenueGrowthProfitMargin
2026 $15M 0% $1.7M 11.6%
2025 $15M 0% $1.7M 11.6%
2024 $15M 0% $1.7M 11.6%
2023 $15M -59.1%
2022 $36M
2021
2020
Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

Diagenode website traffic

Latest recorded traffic for Diagenode is 17K monthly website visits, down 10.5% over the last three months. Diagenode's team declined 10.2% over the past year.

Latest monthly visits17K 3-month web change-10.5% 1-year team growth-10.2%
Monthly website visits125 observations · Jan 2016–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Diagenode compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Talent graph

Diagenode's talent

Book a demo to see the people
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

5 investors on Diagenode's cap table

Sourced from Dealroom's funding and investor records.

Series A 3 investors entered at this stage
Capricorn Partners
Epimede
Wallonie Entreprendre
Other known 2 additional known investors
Hologic
Quest for Growth

Global footprint

Where Diagenode has talent and traffic

Workforce by country
7 countries with
team presence
🇧🇪 Belgium79%
🇺🇸 United States11.6%
🇫🇷 France5.3%
🇮🇹 Italy1.1%
🇯🇵 Japan1.1%
Top 5 of 7 shown

In the news

Latest news about Diagenode

Recent press, funding announcements, and product moves mentioning Diagenode — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Diagenode

An AI-synthesized read of the highest-engagement posts about Diagenode on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Diagenode’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.